Quantitative proteomic analysis in breast cancer

Adel Tabchy, B. T. Hennessy, A. M. Gonzalez-Angulo, F. M. Bernstam, Y. Lu, Gordon Mills

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Much progress has recently been made in the genomic and transcriptional characterization of tumors. However, historically the characterization of cells at the protein level has suffered limitations in reproducibility, scalability and robustness. Recent technological advances have made it possible to accurately and reproducibly portray the global levels and active states of cellular proteins. Protein microarrays examine the native post-translational conformations of proteins including activated phosphorylated states, in a comprehensive high-throughput mode, and can map activated pathways and networks of proteins inside the cells. The reverse-phase protein microarray (RPPA) offers a unique opportunity to study signal transduction networks in small biological samples such as human biopsy material and can provide critical information for therapeutic decision-making and the monitoring of patients for targeted molecular medicine. By providing the key missing link to the story generated from genomic and gene expression characterization efforts, functional proteomics offer the promise of a comprehensive understanding of cancer. Several initial successes in breast cancer are showing that such information is clinically relevant.

Original languageEnglish (US)
Pages (from-to)169-182
Number of pages14
JournalDrugs of Today
Volume47
Issue number2
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Proteomics
Protein Array Analysis
Breast Neoplasms
Molecular Medicine
Protein Conformation
Proteins
Physiologic Monitoring
Signal Transduction
Neoplasms
Decision Making
Biopsy
Gene Expression
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Tabchy, A., Hennessy, B. T., Gonzalez-Angulo, A. M., Bernstam, F. M., Lu, Y., & Mills, G. (2011). Quantitative proteomic analysis in breast cancer. Drugs of Today, 47(2), 169-182. https://doi.org/10.1358/dot.2011.47.2.1576695

Quantitative proteomic analysis in breast cancer. / Tabchy, Adel; Hennessy, B. T.; Gonzalez-Angulo, A. M.; Bernstam, F. M.; Lu, Y.; Mills, Gordon.

In: Drugs of Today, Vol. 47, No. 2, 01.02.2011, p. 169-182.

Research output: Contribution to journalReview article

Tabchy, A, Hennessy, BT, Gonzalez-Angulo, AM, Bernstam, FM, Lu, Y & Mills, G 2011, 'Quantitative proteomic analysis in breast cancer', Drugs of Today, vol. 47, no. 2, pp. 169-182. https://doi.org/10.1358/dot.2011.47.2.1576695
Tabchy A, Hennessy BT, Gonzalez-Angulo AM, Bernstam FM, Lu Y, Mills G. Quantitative proteomic analysis in breast cancer. Drugs of Today. 2011 Feb 1;47(2):169-182. https://doi.org/10.1358/dot.2011.47.2.1576695
Tabchy, Adel ; Hennessy, B. T. ; Gonzalez-Angulo, A. M. ; Bernstam, F. M. ; Lu, Y. ; Mills, Gordon. / Quantitative proteomic analysis in breast cancer. In: Drugs of Today. 2011 ; Vol. 47, No. 2. pp. 169-182.
@article{6c13ee6d5b934596abffccb97d53ecca,
title = "Quantitative proteomic analysis in breast cancer",
abstract = "Much progress has recently been made in the genomic and transcriptional characterization of tumors. However, historically the characterization of cells at the protein level has suffered limitations in reproducibility, scalability and robustness. Recent technological advances have made it possible to accurately and reproducibly portray the global levels and active states of cellular proteins. Protein microarrays examine the native post-translational conformations of proteins including activated phosphorylated states, in a comprehensive high-throughput mode, and can map activated pathways and networks of proteins inside the cells. The reverse-phase protein microarray (RPPA) offers a unique opportunity to study signal transduction networks in small biological samples such as human biopsy material and can provide critical information for therapeutic decision-making and the monitoring of patients for targeted molecular medicine. By providing the key missing link to the story generated from genomic and gene expression characterization efforts, functional proteomics offer the promise of a comprehensive understanding of cancer. Several initial successes in breast cancer are showing that such information is clinically relevant.",
author = "Adel Tabchy and Hennessy, {B. T.} and Gonzalez-Angulo, {A. M.} and Bernstam, {F. M.} and Y. Lu and Gordon Mills",
year = "2011",
month = "2",
day = "1",
doi = "10.1358/dot.2011.47.2.1576695",
language = "English (US)",
volume = "47",
pages = "169--182",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "2",

}

TY - JOUR

T1 - Quantitative proteomic analysis in breast cancer

AU - Tabchy, Adel

AU - Hennessy, B. T.

AU - Gonzalez-Angulo, A. M.

AU - Bernstam, F. M.

AU - Lu, Y.

AU - Mills, Gordon

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Much progress has recently been made in the genomic and transcriptional characterization of tumors. However, historically the characterization of cells at the protein level has suffered limitations in reproducibility, scalability and robustness. Recent technological advances have made it possible to accurately and reproducibly portray the global levels and active states of cellular proteins. Protein microarrays examine the native post-translational conformations of proteins including activated phosphorylated states, in a comprehensive high-throughput mode, and can map activated pathways and networks of proteins inside the cells. The reverse-phase protein microarray (RPPA) offers a unique opportunity to study signal transduction networks in small biological samples such as human biopsy material and can provide critical information for therapeutic decision-making and the monitoring of patients for targeted molecular medicine. By providing the key missing link to the story generated from genomic and gene expression characterization efforts, functional proteomics offer the promise of a comprehensive understanding of cancer. Several initial successes in breast cancer are showing that such information is clinically relevant.

AB - Much progress has recently been made in the genomic and transcriptional characterization of tumors. However, historically the characterization of cells at the protein level has suffered limitations in reproducibility, scalability and robustness. Recent technological advances have made it possible to accurately and reproducibly portray the global levels and active states of cellular proteins. Protein microarrays examine the native post-translational conformations of proteins including activated phosphorylated states, in a comprehensive high-throughput mode, and can map activated pathways and networks of proteins inside the cells. The reverse-phase protein microarray (RPPA) offers a unique opportunity to study signal transduction networks in small biological samples such as human biopsy material and can provide critical information for therapeutic decision-making and the monitoring of patients for targeted molecular medicine. By providing the key missing link to the story generated from genomic and gene expression characterization efforts, functional proteomics offer the promise of a comprehensive understanding of cancer. Several initial successes in breast cancer are showing that such information is clinically relevant.

UR - http://www.scopus.com/inward/record.url?scp=79955941549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955941549&partnerID=8YFLogxK

U2 - 10.1358/dot.2011.47.2.1576695

DO - 10.1358/dot.2011.47.2.1576695

M3 - Review article

C2 - 21431104

AN - SCOPUS:79955941549

VL - 47

SP - 169

EP - 182

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 2

ER -